Reduces Interest Rate by Four Percentage Points and Lowers Required Collateral

TAMPA, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — Upexi, Inc. (NASDAQ: UPXI) (“Upexi” or the “Company”), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it has amended its existing credit facility with BitGo Prime, LLC (“BitGo”), first entered into on May 23, 2025 under a Master Loan Agreement. Under the amended terms, the interest rate applicable to the Company’s outstanding borrowings has been reduced from 11.5% to 7.5% per year, and the required collateral level has been reduced to 200%, with a margin call level of 150%.

“Under the amended credit facility, the Company, based on current borrowings outstanding, expects to save over $2 million in interest costs per year and enjoy greater flexibility with a lower collateral requirement,” stated Allan Marshall, Chief Executive Officer of Upexi. “Such action represents our continued efforts to reduce expenses and fortify the balance sheet as we look for more levers to create value for shareholders.”

About Upexi, Inc.
Upexi, Inc. (Nasdaq: UPXI) is a leading digital asset treasury company, where it aims to acquire and hold as much Solana (SOL) as possible in a disciplined and accretive fashion. In addition to benefiting from the potential price appreciation of Solana, the cryptocurrency of the leading high-performance blockchain, Upexi utilizes three key value accrual mechanisms in intelligent capital issuance, staking, and discounted locked token purchases. The Company operates in a risk-prudent fashion to position itself for any market environment and to appeal to investors of all kinds, and it currently holds over two million SOL. Upexi also continues to be a brand owner specializing in the development, manufacturing, and distribution of consumer products. Please see www.upexi.com for more information.

Follow Upexi on X – https://x.com/upexitreasury
Follow CEO, Allan Marshall, on X – https://x.com/upexiallan
Follow CSO, Brian Rudick, on X – https://x.com/thetinyant

Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. For example, the Company is using forward-looking statements when it discusses the anticipated interest cost savings under the amended credit facility, the availability of borrowings under the facility and its potential future increase, its digital asset treasury strategy, including the accumulation of Solana, and its capital structure. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration, and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Company Contact
Brian Rudick, Chief Strategy Officer
(203) 442-5391
Brian.rudick@upexi.com

Investor Contact
Valter Pinto or Jack Perkins
KCSA Strategic Communications
Upexi@KCSA.com

New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow

WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points has expanded its patent-pending, AI-powered Natural Language Audience Builder (NLAB) tool to allow media planners and buyers to build both claims-grade HCP audiences and privacy-safe direct-to-consumer (DTC) audiences in the same workflow, from a shared plain-language prompt.

This expansion adds OptimizeRx’s Micro-Neighborhood® Targeting (MNT) audiences to NLAB, transforming NLAB from an HCP audience-building solution into a platform-agnostic, no-code audience tool for comprehensive life sciences media planning. From a single patient audience description, marketers can create and optimize both NPI lists and consumer segments in minutes, and then seamlessly activate those audiences across programmatic and other major media channels.

Alongside the addition of MNT audiences, the expansion also adds new optimization and media planning functionality specific to the DTC landscape, including:

  • Decile-based, interactive breakdowns of audience quality (AQ) and reach, so planners can adjust audience precision and scale in real-time to reflect different campaign goals
  • Instant generation of media channel propensities and audience demographics for NLAB-created audiences or natural language audience prompts, so planners can create media mix strategies optimized for their specific brand populations

MNT audiences combine de-identified clinical and consumer data at the ZIP-9 level to create custom, privacy-safe, deterministic audiences with hyperlocal precision, providing a scalable alternative to modeled or probabilistic targeting. As a result of the NLAB integration, non-healthcare-native platforms or marketing agencies can now embed validated healthcare audience intelligence without investing in proprietary data or enterprise data licensing agreements.

“Life sciences marketers need audiences grounded in real healthcare behavior relevant to their brand, not generic segments or modelled proxies,” said Mike Rousselle, Chief AI Officer, OptimizeRx. “By bringing MNT into NLAB, we’re not only giving media planners a more streamlined way to build, refine, and activate consumer audiences, but also enabling the precision that can lead to higher marketing engagement and impact.”

“The more complexity NLAB removes for DSPs, agencies, and their life sciences clients, the easier it becomes to put sophisticated audience intelligence to work,” said Stephen Silvestro, CEO, OptimizeRx. “By making both HCP and consumer audiences available on demand, we can reduce friction for our partners and expand the role OptimizeRx plays across their planning and activation strategies.”

To learn more about NLAB and OptimizeRx’s MNT audience technology, visit www.optimizerx.com/technology.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “allow”, “build”, “transforming”, “can”, “activate”, “embed”, “validate”, “helps” or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the ability of DSPs and agency planners to create deterministic HCP and consumer audiences faster, marketers’ ability to seamlessly activate audiences across programmatic and other major media channels, the ability of non-healthcare-native platforms or marketing agencies to embed validated healthcare audience intelligence without investing in proprietary data or enterprise data licensing agreements, the addition of audiences enabling precision leading to higher marketing engagement and impact, and the ability to reduce friction for the Company’s partners by making HCP and consumer audience available on demand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Jennifer Dinkel, SVP Marketing
jdinkel@optimizerx.com

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
dfarrell@lifesciadvisors.com

Press Inquiries
Matter Communications
optimizerx@matternow.com

Partnership Inquires
Louis Trivento, SVP Strategic Partnerships
ltrivento@optimizerx.com

Vancouver, B.C., Sept. 14, 2026 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI” or the “Company”), a physician-built, AI-powered healthcare technology company focused on empowering doctors and expanding access to high-quality care, is pleased to provide a brief pre-Town Hall operational update highlighting the Company’s progress in some of its key performance indicators for its United States operations during the first two months of the third quarter of 2026.

Following up on the Company’s announced Q2 2026 financial and operational results on September 1, 2026, and ahead of the global Company Town Hall (see details below and announced in a News Release on 9 September, 2026) scheduled for Monday, September 14, 2026, the Company is delighted to share further key recent operational metrics for its U.S. operations.

The objective of this interim update is to place this information in the public domain prior to the Town Hall.

Key U.S. Operational Milestones (July – August 2026)

  • Completed Patient Visits: Completed U.S. patient visits reached 3,625 for the two-month period ending August 31, 2026, representing 93% of the 3,911 completed visits recorded for the entire second quarter (3 months) of 2026.
  • Clinical Hours: U.S. clinical hours increased to 1,555 hours for the two months ending August 31, 2026, representing 78% of the 1,987.5 clinical hours recorded for the entire second quarter of 2026.

Revenue Recognition and Timing Lag

As detailed in the Company’s News Release dated September 1, 2026, it should be noted that because the Company currently recognizes certain U.S. revenues on a cash basis, there is a timing lag between the significant increase in patient visits and the corresponding recognition of revenue.

Further, as described in the Company’s interim Q2 Management’s Discussion and Analysis (“MD&A”), available under its profile on SEDAR+ at www.sedarplus.ca , the following should be noted:

(i) In connection with its U.S. operations, the Company distinguishes between in-network and out-of-network patients when determining reimbursement eligibility for patient visits conducted through its platform. For in-network patients, both the patient and the treating physician must be enrolled with the applicable insurance provider, Medicare, or Medicaid for a reimbursement claim to be eligible for payment. For out-of-network patients, the Company has made a strategic decision to permit access to its platform to drive adoption and expand its user base during this early stage of its U.S. market development.
(ii) While reimbursement for out-of-network visits is generally not expected, the Company will nonetheless submit claims on behalf of these visits where possible, as there remains a possibility that certain claims may be approved at the discretion of the payor.
(iii) Consistent with the Company’s overall revenue recognition policy for its U.S. operations, any amounts recovered in respect of out-of-network claims will only be recognized as revenue upon actual cash receipt, reflecting the heightened uncertainty of collection associated with these visits. Management will continue to evaluate its network coverage and payor relationships with a view to converting out-of-network patients and physicians to in-network status over time, which is expected to improve reimbursement rates and provide greater revenue visibility going forward.

About Rocket Doctor AI Inc.

Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.

Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 750,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices – improving efficiency, restoring autonomy to MDs, and expanding patient access to care.

By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare – making it more scalable, equitable, and patient-centered.

To learn more about Rocket Doctor AI Inc’s products and services, contact: www.rocketdoctor.ai or email: info@rocketdoctor.ai

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO, Rocket Doctor AI essam.hamza@rocketdoctor.ai

Dr. Bill Cherniak, CEO, Rocket Doctor Inc.bill@rocketdoctor.io

For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321

Cautionary Statements

This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects,” “intends,” “plans,” “believes,” “estimates,” “projects,” “forecasts,” “positioned” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Company Town Hall, the Company’s growth strategy for the United States and Canada, the Company’s key U.S. operational milestones including completed patient visits and clinical hours, the timing lag between patient visits and revenue recognition, the Company’s cash-basis revenue recognition policy for U.S. operations, the distinction between in-network and out-of-network patients and the reimbursement eligibility criteria applicable to each, the Company’s strategy to permit out-of-network patient access, the submission of claims for out-of-network visits and the possibility that certain claims may be approved at the discretion of the payor, management’s evaluation of network coverage and payor relationships with a view to converting out-of-network patients and physicians to in-network status, the expected changes in reimbursement rates and revenue, and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. 

Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performances, or achievements expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements due to a number of factors and risks.  Risk factors include, but are not limited to, the Company’s ability to grow its U.S. payer relationships; competition in the digital healthcare and telehealth markets; the Company’s ability to attract and retain physicians and patients on its platform; regulatory risks in the healthcare industry in Canada and the United States; reliance on third-party payers and partners; risks associated with the provider credentialing process, including potential delays in onboarding new providers and the Company’s ability to satisfy growing network capacity requirements within anticipated timeframes; risks relating to the Company’s cash-basis recognition of certain U.S. revenues; general economic conditions; and other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators. Additional risk factors are described in the Company’s continuous disclosure filings available on SEDAR+ at www.sedarplus.ca.

The forward-looking statements and forward-looking information are based on assumptions management considers reasonable, including assumptions regarding the continued growth of the Company’s U.S. patient visit volumes and clinical hours; the ability to maintain and expand the Company’s network of licensed physicians and healthcare providers; the Company’s ability to successfully convert out-of-network patients and physicians to in-network status over time; the continued availability and stability of reimbursement from third-party payers; the expected timing between patient visits and revenue recognition; the continued operation and reliability of the Company’s technology platform; the regulatory environment in Canada and the United States remaining consistent with current conditions; general economic and market conditions; and the Company’s ability to retain key personnel and maintain sufficient working capital to fund its operations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

The Company undertakes no obligation to update forward-looking information except as required by law. This release is not an offer to sell or a solicitation of an offer to buy securities and is not personalized investment advice.

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — With profound sadness, Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) announces the sudden passing of Stephen Scott on September 8, 2026. Mr. Scott served as President, CEO, and a director of the Company for over a decade until his retirement in July 2026.

Mr. Scott worked in the mining industry for more than 30 years, completing his education in Perth, Australia before joining Rio Tinto Exploration (RTX) Australasia. He worked for Rio Tinto for much of his career, including as President Director of Rio Tinto Indonesia, General Manager Commercial for Rio Tinto Canada, and Senior VP Corporate Development and Strategy for Turquoise Hill Resources. In 2014, having firmly established himself in Vancouver, British Columbia, Mr. Scott started a capital markets and management advisory consultancy. He joined Entrée in 2015 and successfully led the Company through restructuring and progressive steps to derisk the Company’s principal mining interest in Mongolia.      

Alan Edwards, Entrée’s Non-Executive Chair of the Board commented, “I had the fortunate privilege of working alongside Steve over the past ten years. He always approached the challenges of leadership with integrity and grace, while maintaining a wry Australian sense of humor. Steve was a wonderful colleague and an even better friend, and he will be greatly missed. On behalf of the Board and management at Entrée, we offer our sincere condolences to Steve’s family and many friends who cared so deeply about him.”

ABOUT ENTRÉE RESOURCES LTD.
Entrée Resources Ltd. is a Canadian mining company with a unique carried joint venture interest on a significant portion of one of the world’s largest copper-gold projects – the Oyu Tolgoi project in Mongolia. Entrée has a 20% or 30% carried participating interest in the Entrée/Oyu Tolgoi joint venture, depending on the depth of mineralization. Royal Gold (through its wholly owned subsidiary International Royalty Corporation) and Rio Tinto are major shareholders of Entrée, beneficially holding approximately 24% and 16% of the shares of the Company, respectively. More information about Entrée can be found at www.EntreeResourcesLtd.com.

FURTHER INFORMATION
David Jan
Investor Relations
Entrée Resources Ltd.
Tel: 604-687-4777 | Toll Free: 1-866-368-7330
E-mail: djan@EntreeResourcesLtd.com

This News Release contains forward-looking information within the meaning of applicable Canadian securities laws.

In certain cases, forward-looking information can be identified by words such as “plans”, “expects” or “does not expect”, “is expected”, “budgeted”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “does not anticipate” or “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will be taken”, “occur” or “be achieved”. While the Company has based this forward-looking information on its expectations about future events as at the date that such information was prepared, the information is not a guarantee of Entrée’s future performance and is based on certain assumptions.

Risks, uncertainties, and factors which could cause actual results, performance, or achievements of the Company to differ materially from future results, performance, or achievements expressed or implied by forward-looking information are discussed in the Company’s most recently filed MD&A and in the Company’s Annual Information Form for the financial year ended December 31, 2025, dated March 5, 2026 filed with the Canadian Securities Administrators and available at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company is under no obligation to update or alter any forward-looking information except as required under applicable securities laws.

Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today highlighted its participation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, held at the Bella Center Copenhagen.

78288f6b8733d8001b7f2ee4aee3aad2

Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA) System to interventional radiologists and healthcare professionals from around the world, providing an opportunity to engage with the global medical community and demonstrate the Company’s technology and approach to minimally invasive ablation.

Baird Medical’s MWA System is designed to deliver precise and controlled ablation and features temperature control technology, stable 2.45 GHz microwave energy delivery, and a range of specialized probes designed to support different clinical applications.

“Participating in CIRSE is an important part of Baird Medical’s continued engagement with the global medical community and reflects the international reach we have built across our business,” said Haimei Wu, Chairwoman and Chief Executive Officer of Baird Medical. “As we continue to strengthen our presence in the U.S. and across global markets, conferences like CIRSE provide valuable opportunities to connect with physicians from around the world, share our technology and deepen the relationships that support the broader adoption of minimally invasive treatment solutions.”

Baird Medical’s participation at CIRSE 2026 reflects the Company’s broader commitment to advancing minimally invasive treatment technologies and strengthening its engagement with physicians and healthcare institutions globally. As the Company continues to expand its presence internationally, most recently in Pakistan, Vietnam, and Argentina, Baird Medical remains focused on providing reliable, precise and versatile technologies designed to support physicians and improve treatment options for patients.

About Baird Medical

Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.

Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled “Risk Factors” therein, and in ExcelFin’s other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin’s most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7e99f8d1-7274-40cd-813c-fe0e717dc3ad

Five-year LOI contemplates purchase of up to 100% of commercially saleable copper and aluminum from Project Headwaters, representing more than $105 million of projected value at current commodity prices.

Agreement follows recently announced WMC Group lithium product offtake framework and further advances the commercial foundation for Aqua Metals’ planned domestic LFP recycling platform

RENO, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), a pioneer in sustainable lithium battery recycling, today announced that it has entered into a letter of intent (“LOI”) with a leading Midwest metals recycler for the purchase of recovered copper and aluminum expected to be produced at Project Headwaters, the Company’s planned commercial-scale lithium-ion battery recycling facility in the Midwestern United States.

Building upon the Company’s previously announced six-year lithium product offtake for the sale of lithium carbonate, Aqua Metals has now established offtake pathways for all three primary Project Headwaters product streams – lithium carbonate, copper and aluminum – in advance of construction.

Under the contemplated five-year agreement, the counterparty would purchase recovered copper and aluminum products from Project Headwaters, subject to product qualification and execution of a definitive agreement. Based on projected production volumes and current commodity prices, the copper and aluminum covered by the LOI represent more than $105 million of projected value over the contemplated five-year term.

The LOI provides a 24-month period to negotiate and execute a definitive offtake agreement. Final product specifications will be based on representative copper and aluminum produced by the Project Headwaters preprocessing system, with product qualification and execution of the definitive agreement expected as the initial phase of the facility begins producing material.

“We now have commercial pathways for every primary product stream at Headwaters, and we have them before we break ground,” said Steve Cotton, President and CEO of Aqua Metals. “Our objective is to build a recycling platform that can compete economically while recovering and keeping valuable battery materials within the domestic supply chain. Establishing commercial pathways for lithium, copper and aluminum materially advances that strategy.”

Copper and aluminum represent important sources of recoverable value from lithium-ion batteries and manufacturing scrap, particularly within the large-format lithium iron phosphate (“LFP”) battery streams Project Headwaters is being designed to process. Certain LFP batteries and manufacturing scrap can also carry processing or recycling fees, creating the potential for recyclers to generate revenue both when material enters the facility and through the sale of recovered products.

Project Headwaters is being designed to capture both sides of that economic opportunity. The planned preprocessing system will separate copper and aluminum from battery materials prior to downstream refining, producing distinct recyclable metal streams for sale into established domestic markets, while Aqua Metals’ proprietary AquaRefining™ technology is intended to recover lithium and other battery materials from the remaining feedstock.

Project Headwaters is being developed as an integrated domestic battery recycling facility combining battery preprocessing with AquaRefining technology. The planned facility is designed to recover and commercialize multiple material streams, including lithium carbonate, copper, aluminum, graphite and iron phosphate-containing materials, rather than relying on a single commodity for project economics.

Together, the lithium carbonate, copper and aluminum LOIs demonstrate Aqua Metals’ progress in establishing commercial outlets across multiple Project Headwaters product streams in advance of construction and commissioning. The Company believes these commercial relationships can help support project financing while reducing future commodity marketing and product-placement risk.

The contemplated copper and aluminum pricing would be tied to prevailing market benchmarks, subject to agreed product specifications and customary commercial terms. The LOI is non-binding and provides a framework for product qualification and negotiation of a definitive offtake agreement.

About Aqua Metals

Aqua Metals is advancing sustainable lithium battery recycling through its proprietary AquaRefining™ technology, an electro-hydrometallurgical process designed to recover critical battery materials using electricity rather than high-temperature processing. The Company is developing Project Headwaters as its first commercial-scale deployment focused on domestic recycling and refining of lithium-ion batteries and manufacturing scrap.

Forward-Looking Statements

This press release contains forward-looking statements, including statements concerning the proposed relationship with the counterparty; execution of a definitive offtake agreement; financing, development, construction, commissioning and operation of Project Headwaters; anticipated production volumes and product values; future commodity prices; product qualification; anticipated recovery and sale of copper and aluminum products; potential processing or recycling fees associated with LFP batteries and manufacturing scrap; the potential impact of U.S. policies supporting domestic critical-mineral processing and refining; and the expected commercial and economic benefits of the contemplated offtake arrangement.

Forward-looking statements are based on current expectations, estimates, assumptions and projections and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, (i) the risk that the Company may not enter into a definitive offtake agreement with the counterparty; (ii) even if it does, the Company’s ability to derive the expected benefits from such agreement; (iii) the Company’s ability to obtain the financing necessary to complete the development of its proposed Project Headwaters facility and otherwise secure long-term site control, negotiate and execute definitive agreements, and obtain permits and approvals concerning Project Headwaters; (iv) the risk that the Company may not be able to obtain the additional capital required to maintain its current level of operations; and (v) those additional risks described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026 and subsequent filings with the Securities and Exchange Commission. Aqua Metals undertakes no obligation to update forward-looking statements except as required by law.

Contacts

For Media and Investor Inquiries: aquametals@icrinc.com

FREMONT, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today announced its participation in AI Infra Summit 2026, from Sept. 15-17, 2026 at the Santa Clara Convention Center in California. Enphase will be at Booth 1454, showcasing its approach to next-generation AI data center power infrastructure, including the IQ® Solid-State Transformer (IQ SST).

On Sept. 15 at 12:00 p.m. PDT, Raghu Belur, co-founder and chief product officer at Enphase Energy, will present “Solid-State Transformers: Speed to Power” on the AI Data Center Track.

The IQ SST is being developed to convert medium-voltage AC directly to 800 VDC for high-density AI data centers, with expected sub-millisecond response to dynamic AI loads. Its distributed architecture is designed to scale to racks up to 5 MW.

“AI data centers are forcing the industry to rethink how power moves from the grid to the rack,” said Raghu Belur. “At AI Infra Summit, we will show how Enphase is applying high-frequency magnetics, GaN power switching, custom silicon, and scalable domestic manufacturing to this challenge.”

Enphase recently began building IQ SST power modules at its manufacturing facility in Arlington, Texas, to assemble and validate full-scale IQ SST racks. A video of the power modules coming off the Enphase manufacturing line is available here.

Full-system demonstrations of IQ SST racks are expected in November 2026, with customer pilots planned for 2027. To learn more about IQ SST, visit the Enphase website.

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems, EV chargers, home energy management systems, and virtual power plant (VPP) solutions. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. The company revolutionized the solar industry with its microinverter-based technology and has shipped approximately 89.4 million microinverters, with approximately 5.3 million Enphase-based systems deployed in over 165 countries. For more information, visit https://enphase.com/.

©2026 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the expected development, validation, performance, product and technology capabilities, architecture, response times, manufacturing and scalability, supply chain, regulatory compliance, commercialization, and timing of full-system demonstrations and customer pilots for Enphase Energy’s IQ Solid-State Transformer (IQ SST). These forward-looking statements are based on Enphase Energy’s current expectations and assumptions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, Enphase Energy’s ability to develop, qualify, manufacture, validate, and commercialize the IQ SST and achieve the targeted technical and system-level performance, including direct conversion of medium-voltage AC to 800 VDC, anticipated sub-millisecond response to dynamic AI loads, and scalability to racks up to 5 MW; the ability to assemble and validate full-scale IQ SST racks and to scale U.S. production and achieve targeted output, yield, and cost; the ability to secure components and cost of supply, including gallium nitride (GaN); the ability of high-frequency magnetics, GaN power switching, custom silicon, and the distributed architecture to perform as intended; the pace and direction of the AI data center industry’s move toward 800 VDC and other changes in data center power architectures; customer adoption; the ability to satisfy applicable regulatory and policy requirements, including domestic content requirements; the timing of full-system demonstrations, customer pilots, and commercialization on the expected timeline; as well as competitive dynamics, execution risks related to entering new markets, and other factors discussed in Enphase Energy’s filings with the Securities and Exchange Commission, including those risks described in more detail in Enphase Energy’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, or changes in its expectations, except as required by law or otherwise.

Contact:

Enphase Energy
press@enphaseenergy.com

Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models. The findings establish a translational foundation for evaluating the compound in a naturally occurring disease setting while the company’s TNBC program simultaneously advances toward site initiation and Phase 1/2 patient enrollment.

Research Findings
Conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology) at Ohio State’s College of Veterinary Medicine, the study examined Telomir-Zn across three osteosarcoma cell line models: HOS (human), D17 (canine), and Abrams (canine). Researchers evaluated the dose-dependent anti-tumor activity of the compound across all three models.

All three osteosarcoma cell lines demonstrated growth inhibition at similar low drug concentrations. “Osteosarcoma in large-breed dogs remains devastating, with limited treatment options and poor outcomes,” noted Bracha, an associate professor at The Ohio State University College of Veterinary Medicine. “These findings suggest Telomir-Zn may offer a meaningful therapeutic opportunity for veterinary patients. The consistency of anti-tumor activity across both canine and human cell lines is particularly compelling because it positions us to explore efficacy in naturally occurring canine osteosarcoma—a model that could accelerate development for both animals and humans.”

These results validate the therapeutic potential of Telomir-Zn in osteosarcoma and support further translational investigation.

Osteosarcoma: An Unmet Clinical Need
Osteosarcoma is the most common primary bone malignancy in children and young adults. Despite decades of chemotherapy-based treatment, survival rates for metastatic disease remain below 30%, with minimal improvement over three decades. In veterinary medicine, osteosarcoma is similarly devastating in large-breed dogs, accounting for the majority of primary bone tumors.

The biological similarities between canine and human osteosarcoma, including genetics, tumor biology, and therapeutic response patterns, make the canine model one of the most clinically predictive disease models available for translational research.

Strategic Development Pathway
Based on these findings, Telomir is assessing osteosarcoma development in canine models as a potential therapeutic pathway, which could support both veterinary indication development and translational advancement toward human osteosarcoma:

  • Track 1: TNBC in Humans — The company’s TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment under an active IND cleared by the FDA, targeting advanced or metastatic triple-negative breast cancer.
  • Track 2: Osteosarcoma in Dogs — Based on these preclinical findings, Telomir is in conversations with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such research could accelerate clinical development in canine and human osteosarcoma.

While the company’s immediate focus remains advancing TNBC toward site initiation and Phase 1/2 patient enrollment, these preclinical findings position potential osteosarcoma development in canine models as a strategic opportunity. If pursued, such a dual-pathway approach could expand the therapeutic indication profile while advancing our platform.

The Iron-Modulation Platform
Telomir-Zn targets intracellular iron and copper homeostasis to modulate epigenetic pathways. The mechanism involves disruption of intracellular labile iron pools and inhibition of iron-dependent histone demethylases (KDMs), which reverses cancer-associated epigenetic silencing.

The company’s strategic focus is triple-negative breast cancer, where the TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment. The osteosarcoma preclinical findings provide an additional translational opportunity to validate the mechanism in a naturally occurring disease model (canine) while simultaneously advancing the lead TNBC indication.

Forward Outlook
Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals, said: “This research opens a strategic opportunity to develop Telomir-Zn across multiple oncology indications. Our TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment, and we are assessing next steps for potential osteosarcoma development. If successful with either indication, this multi-pronged approach could establish Telomir-Zn as a platform therapy targeting aggressive malignancies, meaningfully expanding our therapeutic scope.”

About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit https://telomirpharma.com/.

Telomir Pharmaceuticals Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words.

Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.

Telomir Pharmaceuticals Contact Information
Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

Clinical study to evaluate NS002, the Company’s investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional

Pivotal Study is planned for the fourth quarter of 2026; topline data readout anticipated first quarter 2027

TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE American: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. In addition to the current study approved in the IND, Nasus Pharma plans to initiate its pivotal study in the fourth quarter of 2026 and anticipates topline data readout from the study in the first quarter of 2027.

“FDA clearance of our IND for NS002 is a major development milestone for Nasus and represents a significant step toward the commercialization of this promising asset in a growing $2 billion market,” said Brendan O’Grady, Chief Executive Officer of Nasus Pharma. “Patients living with severe allergies today rely almost exclusively on needle-based autoinjectors. Based on the results from our recent Phase 2 study, which showed NS002 achieving the critical 100 pg/mL plasma epinephrine threshold with a median T100 of 1.69 minutes versus 3.47 minutes for EpiPen®, we believe NS002 presents an opportunity to address a significant unmet medical need for these patients. In a market currently dominated by injectables, NS002’s rapid onset and intranasal administration offer patients and caregivers a potentially superior alternative for treating severe allergic reactions. FDA clearance of our IND application brings us one step closer to offering that alternative to the millions of people at risk of anaphylaxis.”

About Nasus Pharma

Nasus Pharma Ltd. (NYSE American: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company’s lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus Pharma is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: the planned initiation of its pivotal clinical study for NS002 in the fourth quarter of 2026; the anticipation of topline data readout to be in the first quarter of 2027; the growing market for anaphylaxis treatment; and that FDA clearance of the Company’s IND application brings it one step closer to offering a needle-free alternative to millions of people at risk of anaphylaxis. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict, including the risk that the FDA may require additional information or studies before or after the pivotal study, that the pivotal study may not begin or conclude on the timeline the Company currently expects, and that results of the pivotal study may not support further development or approval of NS002. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions.  These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 25, 2026, and other documents filed with or furnished to the SEC which are available on the SEC’s website, www.sec.gov. Forward-looking statements contained in this press release are made as of this date and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact

Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact

Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

Lonquist to lead survey planning and data acquisition, building on recent technical work at Robinsons River

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has engaged Lonquist Field Service (Canada), ULC (“Lonquist”) to manage a targeted ground gravity survey at its 100%-owned Robinsons River Salt Project (the “Project”) in Newfoundland and Labrador. The engagement advances the ground gravity program announced by the Company on September 3, 2026.

Lonquist will coordinate survey planning and oversee third-party gravity data acquisition and processing. The program will build on the recent technical study, with additional measurements intended to fill gaps in existing gravity coverage across selected priority areas. The resulting data will complement the Project’s existing geological, drilling and geophysical information, supporting further evaluation of the subsurface interpretation and potential exploration targets.

“We are pleased to have Lonquist lead this next step at Robinsons River,” said Paul Sparkes, Chief Executive Officer of Vortex. “Their team’s recent technical work has helped identify where additional information would be most useful. This survey will allow us to build on that work and continue advancing our understanding of the Project.”

The survey design, contractor arrangements and schedule are being finalized. Fieldwork remains subject to the Company’s approval of the final program and confirmation of required permits and access arrangements. Vortex will provide further details as planning progresses. Gravity interpretations are non-unique and, on their own, cannot establish salt composition, thickness or continuity.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jared Suchan, Ph.D., P.Geo., Vice President of Exploration of the Company and a “Qualified Person” as defined by National Instrument 43-101.

For additional information concerning the Project and the Company’s data-verification and quality-assurance procedures, readers are referred to the Company’s technical report entitled Independent Technical Report on the Robinsons River Salt Property, dated July 31, 2023, available under the Company’s profile on SEDAR+.

About Vortex Energy Corp.

Vortex Energy Corp. is an exploration stage company engaged principally in the acquisition, exploration, and development of mineral properties in North America. The Company is currently advancing its Robinson River Salt Project comprised of a total of 942 claims covering 23,500 hectares located approximately 35 kilometres south of the town of Stephenville in the Province of Newfoundland & Labrador. The Robinson River Salt Project is prospective for both salt and hydrogen salt cavern storage. The Company is also currently advancing its Fire Eye Uranium Property in the Athabasca Basin, a region renowned for its uranium deposits.

On Behalf of the Board of Directors

Paul Sparkes

Chief Executive Officer, Director

+1 (778) 819-0164

info@vortexenergycorp.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current beliefs or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the Company’s exploration plans at the Project.

Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including, in respect of the forward-looking information included in this press release, assumptions regarding the Company’s ability to execute on its exploration plans, including that it will be successful in carrying out the planned drilling and that such drilling will yield the expected information and the desired outcomes.

Although forward-looking information is based on the reasonable assumptions of the Company’s management, there can be no assurance that any forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among other things, the risk that exploration at the Project does not proceed in the manner and on the timeline currently contemplated, or at all; risks inherent in the exploration and development of mineral deposits, including risks relating to receiving requisite permits and approvals, changes in project parameters or delays as plans continue to be redefined, that mineral exploration is inherently uncertain and that the results of mineral exploration may not be indicative of the actual geology or mineralization of a project; and that mineral exploration may be unsuccessful or fail to achieve the results anticipated by the Company, including as a result of factors beyond the Company’s control, such as geological conditions. The forward-looking information contained in this release is made as of the date hereof, and the Company not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.